Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. The Group and Specialty segment consists of employer group commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Managed Health Care
- Sub-Industry: Managed Health Care
- Symbol: NYSE:HUM
- CUSIP: 44485910
- Web: www.humana.com
- Market Cap: $34.55262 billion
- Outstanding Shares: 144,517,000
- 50 Day Moving Avg: $250.95
- 200 Day Moving Avg: $232.23
- 52 Week Range: $163.50 - $259.76
Sales & Book Value:
- Trailing P/E Ratio: 19.51
- Foreward P/E Ratio: 19.52
- P/E Growth: 1.55
- Annual Revenue: $53.87 billion
- Price / Sales: 0.64
- Book Value: $75.79 per share
- Price / Book: 3.15
- Annual Dividend: $1.60
- Dividend Yield: 0.7%
- EBIDTA: $2.66 billion
- Net Margins: 3.37%
- Return on Equity: 15.85%
- Return on Assets: 5.76%
- Debt-to-Equity Ratio: 0.39%
- Current Ratio: 1.65%
- Quick Ratio: 1.65%
- Average Volume: 1.09 million shs.
- Beta: 0.87
- Short Ratio: 3.51
Frequently Asked Questions for Humana (NYSE:HUM)
What is Humana's stock symbol?
Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."
How often does Humana pay dividends? What is the dividend yield for Humana?
Humana announced a quarterly dividend on Thursday, August 17th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.40 per share on Friday, October 27th. This represents a $1.60 annualized dividend and a yield of 0.67%. The ex-dividend date is Thursday, September 28th. View Humana's Dividend History.
How will Humana's stock buyback program work?
Humana declared that its board has approved a share buyback plan on Tuesday, April 11th 2017, which allows the company to buyback $2,250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 7.3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board believes its shares are undervalued.
How were Humana's earnings last quarter?
Humana Inc. (NYSE:HUM) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported $3.49 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.08 by $0.41. The company earned $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the prior year, the business posted $2.30 earnings per share. View Humana's Earnings History.
When will Humana make its next earnings announcement?
What guidance has Humana issued on next quarter's earnings?
Humana issued an update on its FY17 earnings guidance on Friday, September, 1st. The company provided earnings per share guidance of ~$11.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.51.
Where is Humana's stock going? Where will Humana's stock price be in 2017?
19 analysts have issued 1-year price objectives for Humana's shares. Their forecasts range from $200.00 to $280.00. On average, they anticipate Humana's stock price to reach $245.94 in the next year. View Analyst Ratings for Humana.
Are investors shorting Humana?
Humana saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 2,679,854 shares, a drop of 36.0% from the August 15th total of 4,190,098 shares. Based on an average daily volume of 864,285 shares, the days-to-cover ratio is presently 3.1 days. Approximately 1.9% of the shares of the company are sold short.
Who are some of Humana's key competitors?
Who are Humana's key executives?
Humana's management team includes the folowing people:
- Kurt J. Hilzinger, Independent Chairman of the Board
- Bruce D. Broussard, President, Chief Executive Officer, Director
- Brian A. Kane, Chief Financial Officer, Senior Vice President
- Timothy S. Huval, Chief Human Resource Officer, Senior Vice President
- Brian P. LeClaire, Senior Vice President, Chief Information Officer
- Sam Deshpande, Senior Vice President, Chief Risk Officer
- Christopher M. Todoroff, Senior Vice President, General Counsel
- Roy A. Beveridge M.D., Senior Vice President, Chief Medical Officer
- Jody L. Bilney, Senior Vice President, Chief Consumer Officer
- Christopher H. Hunter, Senior Vice President, Chief Strategy Officer
Who owns Humana stock?
Humana's stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital World Investors (9.16%), BlackRock Inc. (7.76%), Vanguard Group Inc. (6.85%), FMR LLC (4.52%), State Street Corp (4.24%) and Capital Research Global Investors (2.70%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.
Who sold Humana stock? Who is selling Humana stock?
Humana's stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, Capital World Investors, BlackRock Inc., Third Point LLC, Steadfast Capital Management LP, Prudential Financial Inc., Capital Guardian Trust Co. and Davidson Kempner Capital Management LP. Company insiders that have sold Humana stock in the last year include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy S Huval and William Kevin Fleming. View Insider Buying and Selling for Humana.
Who bought Humana stock? Who is buying Humana stock?
Humana's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Koch Industries Inc., Acadian Asset Management LLC, TIAA CREF Investment Management LLC, Ameriprise Financial Inc., Capital Research Global Investors and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Humana.
How do I buy Humana stock?
Shares of Humana can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Humana's stock price today?
MarketBeat Community Rating for Humana (NYSE HUM)MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Humana stock can currently be purchased for approximately $239.09.
Consensus Ratings for Humana (NYSE:HUM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Hold Ratings, 12 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.63)|
|Consensus Price Target: ||$245.94 (2.87% upside)|
Analysts' Ratings History for Humana (NYSE:HUM)
(Data available from 9/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/20/2017||Cowen and Company||Reiterated Rating||Outperform||$230.00 -> $275.00||Medium|
|8/17/2017||Morgan Stanley||Boost Price Target||Overweight||$269.00 -> $276.00||Low|
|8/7/2017||Deutsche Bank AG||Boost Price Target||Hold||$234.00 -> $243.00||Low|
|8/4/2017||Jefferies Group LLC||Reiterated Rating||Hold||$257.00||Low|
|8/3/2017||Cantor Fitzgerald||Reiterated Rating||Neutral||$200.00 -> $223.00||Low|
|8/3/2017||Oppenheimer Holdings, Inc.||Boost Price Target||Outperform||$236.00 -> $255.00||Medium|
|8/3/2017||Credit Suisse Group||Reiterated Rating||Outperform||$250.00 -> $260.00||High|
|8/3/2017||Piper Jaffray Companies||Boost Price Target||Overweight||$280.00||High|
|7/14/2017||Bank of America Corporation||Boost Price Target||Buy||$270.00 -> $275.00||Low|
|6/28/2017||Citigroup Inc.||Initiated Coverage||Buy -> Buy||$275.00||Medium|
|6/9/2017||Argus||Upgrade||Hold -> Buy||$260.00||Low|
|6/5/2017||Royal Bank Of Canada||Reiterated Rating||Hold||$214.00||Low|
|5/30/2017||Leerink Swann||Boost Price Target||Outperform||$250.00 -> $265.00||Low|
|4/25/2017||Evercore ISI||Reiterated Rating||Outperform||$240.00||Low|
|1/24/2017||Stifel Nicolaus||Downgrade||Buy -> Hold||$214.00 -> $210.00||N/A|
|1/9/2017||Barclays PLC||Reiterated Rating||Hold||$217.00||N/A|
|12/4/2016||Susquehanna Bancshares Inc||Reiterated Rating||Neutral||$180.00 -> $200.00||N/A|
|11/10/2016||J P Morgan Chase & Co||Upgrade||Neutral -> Overweight||$163.00 -> $202.00||N/A|
|7/22/2016||FBR & Co||Lower Price Target||Mkt Perform||$220.00 -> $170.00||N/A|
Earnings History for Humana (NYSE:HUM)Earnings History by Quarter for Humana (NYSE HUM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||$3.08||$3.49||$13.61 billion||$13.53 billion||View||Listen|
|5/3/2017||Q1 2017||$2.55||$2.75||$13.61 billion||$13.76 billion||View||N/A|
|2/8/2017||Q416||$2.05||$2.09||$13.55 billion||$12.88 billion||View||N/A|
|11/4/2016||Q316||$3.09||$3.18||$13.41 billion||$13.69 billion||View||N/A|
|8/3/2016||Q216||$2.23||$2.30||$13.59 billion||$14.00 billion||View||N/A|
|5/4/2016||Q1||$1.81||$1.86||$13.80 billion||$13.80 billion||View||N/A|
|2/10/2016||Q415||$1.45||$1.45||$13.51 billion||$13.40 million||View||N/A|
|11/6/2015||Q315||$2.13||$2.16||$13.64 billion||$13.36 billion||View||N/A|
|7/29/2015||Q215||$1.63||$1.67||$13.81 billion||$13.73 billion||View||N/A|
|4/29/2015||Q115||$2.54||$2.47||$13.51 billion||$13.80 billion||View||Listen|
|2/4/2015||Q414||$1.16||$1.09||$12.41 billion||$12.23 million||View||Listen|
|11/7/2014||Q314||$2.01||$1.85||$12.34 billion||$12.24 billion||View||Listen|
|7/30/2014||Q214||$2.19||$2.19||$11.93 billion||$12.22 billion||View||Listen|
|5/7/2014||Q114||$1.94||$2.35||$11.45 billion||$11.71 billion||View||Listen|
|2/5/2014||Q413||$0.95||($0.19)||$10.23 billion||$10.20 billion||View||Listen|
|11/6/2013||Q313||$2.14||$2.31||$10.27 billion||$10.00 billion||View||Listen|
|7/31/2013||Q2 2013||$2.46||$2.63||$10.36 billion||$10.32 billion||View||Listen|
|5/1/2013||Q1 2013||$1.80||$2.95||$10.23 billion||$10.49 billion||View||Listen|
|2/4/2013||Q4 2012||$1.07||$1.19||$9.73 billion||$9.56 billion||View||Listen|
|11/5/2012||Q312||$2.05||$2.62||$9.86 billion||$9.65 billion||View||N/A|
Earnings Estimates for Humana (NYSE:HUM)
2017 EPS Consensus Estimate: $10.86
2018 EPS Consensus Estimate: $12.20
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Humana (NYSE:HUM)
|Dividend Growth:||3.10% (3 Year Average)|
|Payout Ratio:||13.06% (Trailing 12 Months of Earnings) |
13.86% (Based on This Year's Estimates)
13.06% (Based on Next Year's Estimates)
|Track Record:||6 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Humana (NYSE HUM)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Humana (NYSE:HUM)
Insider Ownership Percentage: 0.80%Insider Trades by Quarter for Humana (NYSE:HUM)
Institutional Ownership Percentage: 95.12%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/1/2017||Elizabeth D Bierbower||Insider||Sell||9,786||$259.00||$2,534,574.00|| |
|9/1/2017||Timothy S Huval||VP||Sell||7,803||$258.14||$2,014,266.42|| |
|8/23/2017||William Kevin Fleming||Insider||Sell||3,071||$250.98||$770,759.58|| |
|8/11/2017||Bruce D Broussard||CEO||Sell||12,000||$251.88||$3,022,560.00|| |
|8/10/2017||M Todoroff Christopher||VP||Sell||22,935||$252.52||$5,791,546.20|| |
|6/28/2017||Brian P Leclaire||SVP||Sell||4,971||$240.00||$1,193,040.00|| |
|5/26/2017||Heidi S Margulis||VP||Sell||1,500||$231.96||$347,940.00|| |
|5/5/2017||Jody L Bilney||SVP||Sell||4,600||$230.16||$1,058,736.00|| |
|5/4/2017||Bruce D Broussard||CEO||Sell||118,231||$225.82||$26,698,924.42|| |
|5/4/2017||Timothy S Huval||VP||Sell||13,939||$225.86||$3,148,262.54|| |
|3/21/2017||Jody L Bilney||SVP||Sell||4,348||$213.80||$929,602.40|| |
|3/6/2017||James E Murray||COO||Sell||31,151||$213.62||$6,654,476.62|| |
|3/3/2017||Cynthia H Zipperle||VP||Sell||1,885||$213.37||$402,202.45|| |
|2/24/2017||Brian P Leclaire||SVP||Sell||4,971||$204.81||$1,018,110.51|| |
|2/22/2017||Brian P Leclaire||SVP||Sell||26,894||$205.24||$5,519,724.56|| |
|2/22/2017||James E Murray||COO||Sell||9,523||$204.69||$1,949,262.87|| |
|2/22/2017||Roy A Beveridge||VP||Sell||4,832||$205.73||$994,087.36|| |
|2/21/2017||Bruce D Broussard||CEO||Sell||104,256||$205.23||$21,396,458.88|| |
|2/21/2017||Cynthia H Zipperle||CAO||Sell||4,213||$204.67||$862,274.71|| |
|2/21/2017||David A. Jr/Ky Jones||Director||Sell||27,000||$205.04||$5,536,080.00|| |
|2/21/2017||James E Murray||COO||Sell||70,332||$205.20||$14,432,126.40|| |
|2/21/2017||Jody L Bilney||SVP||Sell||6,087||$204.72||$1,246,130.64|| |
|2/21/2017||M Todoroff Christopher||VP||Sell||24,140||$205.33||$4,956,666.20|| |
|2/25/2016||Brian P Leclaire||SVP||Sell||183||$176.11||$32,228.13|| |
|3/11/2015||James E Murray||COO||Sell||35,220||$160.90||$5,666,898.00|| |
|3/2/2015||Brian P Leclaire||SVP||Sell||5,500||$161.79||$889,845.00|| |
|2/25/2015||Bruce D Broussard||CEO||Sell||41,105||$165.29||$6,794,245.45|| |
|2/25/2015||David A Jr/Ky Jones||Director||Sell||6,100||$165.39||$1,008,879.00|| |
|2/24/2015||Heidi S Margulis||VP||Sell||3,665||$164.44||$602,672.60|| |
|8/22/2014||Brian P Leclaire||SVP||Sell||3,250||$123.04||$399,880.00|| |
|5/15/2014||Heidi Margulis||VP||Sell||3,345||$119.56||$399,928.20|| |
|5/12/2014||Marissa Peterson||Director||Sell||2,026||$123.30||$249,805.80|| |
|3/19/2014||James Murray||COO||Sell||36,833||$116.59||$4,294,359.47|| |
|3/18/2014||M Todoroff Christopher||VP||Sell||8,000||$113.20||$905,600.00|| |
|3/13/2014||Bruce Broussard||CEO||Sell||109,000||$109.84||$11,972,560.00|| |
|3/10/2014||Webster Roy Dunbar||Director||Sell||9,587||$110.30||$1,057,446.10|| |
|12/4/2013||Marissa Peterson||Director||Sell||1,147||$103.54||$118,760.38|| |
|12/2/2013||M Todoroff Christopher||VP||Sell||6,000||$105.50||$633,000.00|| |
|11/26/2013||Heidi Margulis||VP||Sell||5,500||$104.42||$574,310.00|| |
|11/8/2013||David Jr/Ky Jones||Director||Sell||11,000||$95.00||$1,045,000.00|| |
|9/5/2013||Elizabeth D Bierbower||Insider||Sell||17,673||$96.01||$1,696,784.73|| |
|8/30/2013||Heidi Margulis||VP||Sell||3,319||$93.35||$309,828.65|| |
|8/29/2013||David Jr/Ky Jones||Director||Sell||2,500||$93.01||$232,525.00|| |
|8/23/2013||Elizabeth Bierbower||Insider||Sell||6,063||$94.00||$569,922.00|| |
|8/15/2013||Michael Mccallister||Director||Sell||138,817||$91.49||$12,700,367.33|| |
|8/13/2013||Bruce Perkins||Insider||Sell||9,000||$93.47||$841,230.00|| |
|8/8/2013||Steven Mcculley||VP||Sell||10,000||$92.54||$925,400.00|| |
|8/7/2013||James Bloem||CFO||Sell||33,000||$91.79||$3,029,070.00|| |
|8/1/2013||M Todoroff Christopher||VP||Sell||39,596||$90.30||$3,575,518.80|| |
|6/24/2013||Paul B K Kusserow||SVP||Sell||34,219||$84.60||$2,894,927.40|| |
|6/18/2013||Elizabeth D Bierbower||Insider||Sell||8,033||$83.29||$669,068.57|| |
|5/30/2013||James E Murray||COO||Sell||11,000||$81.96||$901,560.00|| |
|5/9/2013||Michael B Mccallister||Director||Sell||281,312||$77.72||$21,863,568.64|| |
Headline Trends for Humana (NYSE:HUM)
Latest Headlines for Humana (NYSE:HUM)
Humana (HUM) Chart for Tuesday, September, 26, 2017